Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...
Novo Nordisk is working on a new obesity drug that could help patients ... Semaglutide, the GLP-1 drug that Novo sells under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback